U.S. markets closed
  • S&P 500

    4,070.56
    +10.13 (+0.25%)
     
  • Dow 30

    33,978.08
    +28.67 (+0.08%)
     
  • Nasdaq

    11,621.71
    +109.30 (+0.95%)
     
  • Russell 2000

    1,911.46
    +8.39 (+0.44%)
     
  • Crude Oil

    79.38
    -1.63 (-2.01%)
     
  • Gold

    1,943.90
    -2.80 (-0.14%)
     
  • Silver

    23.73
    -0.30 (-1.23%)
     
  • EUR/USD

    1.0874
    -0.0018 (-0.16%)
     
  • 10-Yr Bond

    3.5180
    +0.0250 (+0.72%)
     
  • GBP/USD

    1.2395
    -0.0012 (-0.10%)
     
  • USD/JPY

    129.8000
    -0.3530 (-0.27%)
     
  • BTC-USD

    23,230.46
    +169.87 (+0.74%)
     
  • CMC Crypto 200

    526.66
    +9.65 (+1.87%)
     
  • FTSE 100

    7,765.15
    +4.04 (+0.05%)
     
  • Nikkei 225

    27,382.56
    +19.81 (+0.07%)
     

AC Immune's Alzheimer's Vaccine Candidate Elicit Response In Early-Stage Study; Shares Rally

  • AC Immune SA (NASDAQ: ACIU) soars in premarket on robust volume, on the heels of positive interim results from its ongoing Phase 1b/2a trial evaluating its anti-phospho-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer's disease.

  • ACI-35.030 is under development in collaboration with Johnson & Johnson's (NYSE: JNJ) Janssen Pharmaceuticals under a 2014 agreement.

  • Data shows that after the first injection of ACI-35.030, both lowest and second highest dosages, 100% of the patients demonstrated a potent antigen-specific antibody response against pTau, achieving antibody levels much higher than pre-vaccination levels. It does not show clinically relevant adverse events.

  • The company says that anti-pTau vaccination generates antibody responses with pharmacokinetic characteristics and target epitopes that differ substantially from the company's anti-Tau monoclonal antibody semorinemab.

  • The third and highest dosing group, per the study protocol, is up next.

  • The 32-subject trial's primary objective is to assess the safety, tolerability, and immunogenicity of different doses of ACI-35.030 over a 48-week in patients with early AD. Other endpoints will assess clinical and cognitive parameters as well as additional immunogenicity and safety parameters.

  • Price Action: ACIU gained 117.7% at $15.87 in premarket trading on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.